This MSA secures a reliable supply of cGMP Re-186, the radioisotope used in Plus Therapeutics’ lead radiotherapeutic candidate Rhenium (186Re) Obisbemeda. “This continuing agreement with Telix ...
This MSA secures a reliable supply of cGMP Re-186, the radioisotope used in Plus Therapeutics’ lead radiotherapeutic candidate Rhenium (186 Re) Obisbemeda. “This continuing agreement with ...
Plus Therapeutics presents ReSPECT-LM phase 1 trial data for breast cancer patients with leptomeningeal metastases: Austin, Texas Friday, December 20, 2024, 18:00 Hrs [IST] Plus T ...
Plus Therapeutics (PSTV) presented data updating the progress of its ReSPECT-LM Phase 1 clinical trial of Rhenium Obisbemeda in leptomeningeal disease with a specific focus on breast cancer patients.
Heilongjiang Provincial Key Laboratory of CO2 Resource Utilization and Energy Catalytic Materials, School of Material Science and Chemical Engineering, Harbin University of Science and Technology, ...